Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Other financing activities (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed Other financing activities for 5 consecutive years, with $368000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other financing activities rose 1500.0% to $368000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $489000.0, a 20.1% decrease, with the full-year FY2024 number at $290000.0, down 92.06% from a year prior.
  • Other financing activities was $368000.0 for Q3 2025 at Lyra Therapeutics, up from $23000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $4.0 million in Q2 2022 to a low of $2000.0 in Q1 2022.
  • A 5-year average of $522272.7 and a median of $169000.0 in 2024 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: plummeted 94.52% in 2024, then soared 1500.0% in 2025.
  • Lyra Therapeutics' Other financing activities stood at $4000.0 in 2021, then soared by 5800.0% to $236000.0 in 2022, then skyrocketed by 36.44% to $322000.0 in 2023, then crashed by 92.86% to $23000.0 in 2024, then skyrocketed by 1500.0% to $368000.0 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Other financing activities are $368000.0 (Q3 2025), $23000.0 (Q3 2024), and $98000.0 (Q2 2024).